Program
pemigatinib
Also written as “Pemigatinib”.
Its studies are mostly in Cholangiocarcinoma · Carcinoma, Transitional Cell · Glioblastoma · Neoplasms, Unknown Primary · Myeloproliferative Disorders, led by 3 companies.
Drug pagePemigatinib: every studyAll 46 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Incyteits history only | 131 open or running | phase 3since Aug 29, 2018 | Jan 30, 2015 | Feb 25, 2031phase 2 · NCT07862998 |
| Innovent Biologicsits history only | 20 open or running | phase 2since Jan 20, 2020 | Jan 20, 2020 | none ahead |
| Hoffmann-La Roche | 10 open or running | phase 2since Apr 5, 2018 | Apr 5, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2017Named pemigatinibINNProposed as its International Nonproprietary Name in WHO's List 118
- Apr 5, 2018First study: phase 2 study in Neoplasms, Unknown PrimaryFirst studyNCT03498521 · 529 enrolled · Australia, Austria, Brazil and more
TargetBeta
“An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), ”NCIt, by rule
“Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| infigratinibrule | BridgeBio | phase 3 | 17 |
| futibatinibrule | Otsuka | phase 3 | 10 |
Studies
The one study Hoffmann-La Roche leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03498521Neoplasms, Unknown Primary · Australia, Austria, Brazil and more | 2 | Completed | Feb 14, 2023 | 529 |
How it is read
Names in the registry
- “Pemigatinib”, 15 entries
- “pemigatinib”, 2 entries
Conditions, from the studies’ own filings
- Cholangiocarcinoma, 4 studies
- Carcinoma, Transitional Cell, 2 studies
- Glioblastoma, 1 study
- Neoplasms, Unknown Primary, 1 study
- Myeloproliferative Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.